Research programme: anti-neurotensin receptor 1 antibodies - Immune Biosolutions
Latest Information Update: 28 Feb 2023
At a glance
- Originator Immune Biosolutions
- Class Antibodies; Antihyperglycaemics; Antineoplastics; Obesity therapies
- Mechanism of Action Neurotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Colorectal cancer; Diabetes mellitus; Obesity
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Colorectal-cancer in Canada (Parenteral)
- 28 Feb 2023 No recent reports of development identified for research development in Diabetes-mellitus in Canada (Parenteral)
- 28 Feb 2023 No recent reports of development identified for research development in Obesity in Canada (Parenteral)